Table 3 Bivariate subgroup analysis of patients with high or low BSI lesions combined with either Bcl-2−/+ or p53−/+ or MSI−/+ samples in relation to 5-year DFS and 5-year OS (log-rank test)

From: Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX

 

n

5-year DFS (%)

P

5-year OS (%)

P

BSI high/Bcl-2−

24

82.6

0.2

87.1

0.2

BSI high/Bcl-2+

87

68.8

 

73.1

 

BSI low/Bcl-2−

33

56.8

0.7

59.5

0.7

BSI low/Bcl-2+

44

41.4

 

61.4

 

BSI high/p53−

58

80.7

0.03

80.8

0.07

BSI high/p53+

53

61.9

 

70.9

 

BSI low/p53−

36

45.5

0.7

58.5

0.8

BSI low/p53+

41

50.4

 

62.6

 

BSI high/MSI−

97

68.6

0.11

73.7

0.13

BSI high/MSI+

7

100

 

100

 

BSI low/MSI−

61

44.4

1

58.6

0.9

BSI low/MSI+

9

55.6

 

66.7

 
  1. BSI=BAX staining index; DFS=disease-free survival; 5-FU=5-fluorouracil; LEV=levamisole; MSI=microsatellite instability; OS=overall survival. Bold values signify P<0.05.
Back to article page